Mauro Giordano

Dr. Mauro Giordano

University of Campania "Luigi Vanvitelli", Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TCTiziana Ciarambino
Tiziana Ciarambino
GMGiovanni Menna
Giovanni Menna
GSGennaro Sansone
Gennaro Sansone
MGMauro Giordano
Mauro Giordano
Background: Cardiomyopathies are a heterogeneous group of pathologies characterized by structural and functional alterations of the heart. Aims: The purpose of this narrative review is to focus on the most important cardiomyopathies and their epidemiology, diagnosis, and management. Methods: Clinical trials were identified by Pubmed until 30 March 2021. The search keywords were “cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy (ARCV), takotsubo syndrome”. Results: Hypertrophic cardiomyopathy (HCM) is the most common primary cardiomyopathy, with a prevalence of 1:500 persons. Dilated cardiomyopathy (DCM) has a prevalence of 1:2500 and is the leading indication for heart transplantation. Restrictive cardiomyopathy (RCM) is the least common of the major cardiomyopathies, representing 2% to 5% of cases. Arrhythmogenic cardiomyopathy (ARCV) is a pathology characterized by the substitution of the myocardium by fibrofatty tissue. Takotsubo cardiomyopathy is defined as an abrupt onset of left ventricular dysfunction in response to severe emotional or physiologic stress. Conclusion: In particular, it has been reported that HCM is the most important cause of sudden death on the athletic field in the United States. It is needless to say how important it is to know which changes in the heart due to physical activity are normal, and when they are pathological.

13 April 2017 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
ECEmanuela Cataudella
Emanuela Cataudella
CGChiara M. Giraffa
Chiara M. Giraffa
SMSalvatore Di Marca
Salvatore Di Marca
APAlfredo Pulvirenti
Alfredo Pulvirenti
Salvatore AlaimoSalvatore Alaimo
Salvatore Alaimo
Lorenzo MalatinoLorenzo Malatino
Lorenzo Malatino

10 February 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
LRLuca Rinaldi
Luca Rinaldi
PPPia Clara Pafundi
Pia Clara Pafundi
RGRaffaele Galiero
Raffaele Galiero
Alfredo CaturanoAlfredo Caturano
Alfredo Caturano
MMMARIA VITTORIA MORONE
MARIA VITTORIA MORONE
FSFerdinando Carlo Sasso
Ferdinando Carlo Sasso
Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical and physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS, and both clinical and histologic liver picture. NAFLD and IR are bidirectionally correlated and, consequently, the development of pre-diabetes and diabetes is the most direct consequence at the extrahepatic level. In turn, type 2 diabetes is a well-known risk factor for multiorgan damage, including an involvement of cardiovascular system, kidney and peripheral nervous system. The increased MS incidence worldwide, above all due to changes in diet and lifestyle, is associated with an equally significant increase in NAFLD, with a subsequent rise in both morbidity and mortality due to both metabolic, hepatic and cardiovascular diseases. Therefore, the slowdown in the increase of the “bad company” constituted by MS and NAFLD, with all the consequent direct and indirect costs, represents one of the main challenges for the National Health Systems.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LALuigi Elio Adinolfi
Luigi Elio Adinolfi
RNRiccardo Nevola
Riccardo Nevola
GLGiacomo Lus
Giacomo Lus
LRLuciano Restivo
Luciano Restivo
BGBarbara Guerrera
Barbara Guerrera
AMAldo Marrone
Aldo Marrone
Hepatitis C virus (HCV) infection is considered a systemic disease because of involvement of other organs and tissues concomitantly with liver disease. Among the extrahepatic manifestations, neuropsychiatric disorders have been reported in up to 50% of chronic HCV infected patients. Both the central and peripheral nervous system may be involved with a wide variety of clinical manifestations. Main HCV-associated neurological conditions include cerebrovascular events, encephalopathy, myelitis, encephalomyelitis, and cognitive impairment, whereas “brain fog”, depression, anxiety, and fatigue are at the top of the list of psychiatric disorders. Moreover, HCV infection is known to cause both motor and sensory peripheral neuropathy in the context of mixed cryoglobulinemia, and has also been recently recognized as an independent risk factor for stroke. These extrahepatic manifestations are independent of severity of the underlying chronic liver disease and hepatic encephalopathy. The brain is a suitable site for HCV replication, where the virus may directly exert neurotoxicity; other mechanisms proposed to explain the pathogenesis of neuropsychiatric disorders in chronic HCV infection include derangement of metabolic pathways of infected cells, alterations in neurotransmitter circuits, autoimmune disorders, and cerebral or systemic inflammation. A pathogenic role for HCV is also suggested by improvement of neurological and psychiatric symptoms in patients achieving a sustained virologic response following interferon treatment; however, further ad hoc trials are needed to fully assess the impact of HCV infection and specific antiviral treatments on associated neuropsychiatric disorders.

1 May 2000 in Atherosclerosis
Verified
Journal Article
Closed access
Giuseppe PaolissoGiuseppe Paolisso
Giuseppe Paolisso
MBMara Barbagallo
Mara Barbagallo
GPGiuseppina Petrella
Giuseppina Petrella
EREmilia Ragno
Emilia Ragno
MBMichelangela Barbieri
Michelangela Barbieri
MVMichele Varricchio
Michele Varricchio

Verified
Journal Article
Open access
PDF file
LALuigi Elio Adinolfi
Luigi Elio Adinolfi
LRLuca Rinaldi
Luca Rinaldi
BGBarbara Guerrera
Barbara Guerrera
LRLuciano Restivo
Luciano Restivo
AMAldo Marrone
Aldo Marrone
RZRosa Zampino
Rosa Zampino
The aim of this paper is to review and up to date the prevalence of hepatitis C virus (HCV)-associated non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their significance in both accelerating progression of HCV-related liver disease and development of HCV-associated extrahepatic diseases. The reported mean prevalence of HCV-related NAFLD was 55%, whereas NASH was reported in 4%–10% of cases. HCV genotype 3 directly induces fatty liver deposition, namely “viral steatosis” and it is associated with the highest prevalence and degree of severity, whereas, HCV non-3 genotype infection showed lower prevalence of steatosis, which is associated with metabolic factors and insulin resistance. The host’s genetic background predisposes him or her to the development of steatosis. HCV’s impairment of lipid and glucose metabolism causes fatty liver accumulation; this seems to be a viral strategy to optimize its life cycle. Irrespective of insulin resistance, HCV-associated NAFLD, in a degree-dependent manner, contributes towards accelerating the liver fibrosis progression and development of hepatocellular carcinoma by inducing liver inflammation and oxidative stress. Furthermore, NAFLD is associated with the presence of metabolic syndrome, type 2 diabetes, and atherosclerosis. In addition, HCV-related “metabolic steatosis” impairs the response rate to interferon-based treatment, whereas it seems that “viral steatosis” may harm the response rate to new oral direct antiviral agents. In conclusion, a high prevalence of NAFLD occurs in HCV infections, which is, at least in part, induced by the virus, and that NAFLD significantly impacts progression of the liver disease, therapeutic response, and some extrahepatic diseases.